EMMA (Emmaus Life Sciences) Tariff Resilience Score: 5/10 (As of Jun. 28, 2026)


What is Emmaus Life Sciences Tariff Resilience Score?

Emmaus Life Sciences EMMA Tariff Resilience Score is 5 as of Jun. 28, 2026. The stock has 6 warning signs investors should review. Among 1,376 Biotechnology companies, Emmaus Life Sciences ranks better than 62.21% on this metric.

Emmaus Life Sciences has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

Emmaus Life Sciences has Pharmaceuticals face potential tariffs on imported raw materials. Limited alternative suppliers and pricing constraints in healthcare markets pose challenges.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Emmaus Life Sciences might have Average Resilient.

Emmaus Life Sciences  (OTCPK:EMMA) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Emmaus Life Sciences Tariff Resilience Score Related Terms

EMMA vs CERO, AGTX, WINT: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Emmaus Life Sciences's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Emmaus Life Sciences Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Emmaus Life Sciences's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Emmaus Life Sciences's Tariff Resilience Score falls into.


What does a Tariff Resilience Score of 5 mean?
Emmaus Life Sciences (EMMA) has a Tariff Resilience Score of 5 as of Jun. 28, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Emmaus Life Sciences ranks #520 out of 1376 companies in the Biotechnology industry, placing it in the top 37.8%.
Is Emmaus Life Sciences' Tariff Resilience Score too high?
Emmaus Life Sciences' current Tariff Resilience Score is 5. The Biotechnology industry median Tariff Resilience Score is 4.00. Emmaus Life Sciences' value of 5 is 25% above this industry median. Based on the distribution chart, Emmaus Life Sciences ranks #520 out of 1376 companies in the Biotechnology industry, which is above the industry midpoint.
How does Emmaus Life Sciences' Tariff Resilience Score compare to CERO and AGTX?
According to the Biotechnology industry distribution chart, Emmaus Life Sciences ranks #520 out of 1376 companies for Tariff Resilience Score. This puts Emmaus Life Sciences in the upper half of its industry. The industry median Tariff Resilience Score is 4.00. Emmaus Life Sciences' value of 5 is 25% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,376 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Emmaus Life Sciences's current Tariff Resilience Score of 5 is 25% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Emmaus Life Sciences's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emmaus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Emmaus Life Sciences (EMMA) is currently considered Fairly Valued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading right at its estimated fair value. The current Tariff Resilience Score is 5 and 25% above the Biotechnology industry median of 4.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Emmaus Life Sciences (EMMA), the current Tariff Resilience Score is 5 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Emmaus Life Sciences Business Description

Address 21250 Hawthorne Boulevard, Suite 800, Torrance, CA, USA, 90503
Emmaus Life Sciences Inc is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sales of the Company's product Endari (prescription grade L-glutamine oral powder), to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari is reimbursable by the Centers for Medicare and Medicaid Services, and every state provides coverage for Endari for outpatient prescriptions to all eligible Medicaid enrollees within their state Medicaid programs. Endari is also reimbursable by many commercial payors.